REGISTERED NUMBER: 09927036 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2024

for

Renown Pharma Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

Dr A Clarke

R A B Stewart

REGISTERED OFFICE:

10 Station Road

Henley on Thames

Oxfordshire

RG9 1AY

REGISTERED NUMBER:

09927036 (England and Wales)

ACCOUNTANTS:

Ridgefield Consulting Ltd

2 Hinksey Court

Church Way

Oxford

Oxfordshire

OX2 9SX

FIXED ASSETS

Investments

4

900

900

CURRENT ASSETS

Debtors

5

340,438

337,335

CREDITORS

Amounts falling due within one year

6

470,644

453,311

NET CURRENT LIABILITIES

(130,206

)

(115,976

)

TOTAL ASSETS LESS CURRENT LIABILITIES

(129,306

)

(115,076

)

CAPITAL AND RESERVES

Called up share capital

7

1,000

1,000

Retained earnings

(130,306

)

(116,076

)

SHAREHOLDERS' FUNDS

(129,306

)

(115,076

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 September 2025 and were signed on its behalf by:

Dr A Clarke - Director

1.	STATUTORY INFORMATION

Renown Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and at least the next 12 months from the signing of the financial statements. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4.	FIXED ASSET INVESTMENTS

Other

investments

£

COST

At 1 January 2024

and 31 December 2024

900

NET BOOK VALUE

At 31 December 2024

900

At 31 December 2023

900

The company's investments at the Balance Sheet date in the share capital of companies include the following:

US3 Partnership LLP

Registered office: England & Wales

Nature of business:

%

Class of shares:

holding

Designated Member

100.00

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Amounts owed by group undertakings

340,383

337,280

Other debtors

55

55

340,438

337,335

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Other creditors

470,644

453,311

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.12.24

31.12.23

value:

£

£

1,000

Ordinary

1

1,000

1,000

8.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

At the start of the year, the Company owed a director £8,355. This amount was still owed at the year end.

9.	RELATED PARTY DISCLOSURES

At the start of the year, the Company owed US$450,000 to a shareholder, upon which the Company is being charged interest at 3.5%. This loan had not been repaid by the year end.

Ricanto Limited is a related party by virtue of common directors. At the start of the year, Ricanto Ltd owed the Company £154,037. During the year, Ricanto Limited paid expenses on behalf of the Company of £4,976 (2022: £nil). At the year end, Ricanto Limited owed the Company £140,899, after adjusting for a foreign exchange loss of £8,162 (2022: gain of £17,512).

Renown Pharma Inc. is a related party by virtue of common directors. At the start of the year, Renown Pharma Inc. owed the Company £206,584. At the year end, Renown Pharma Inc. owed the Company £196,382, after adjusting for a foreign exchange loss of £10,202 (2022: gain of £21,889).